Clinical Trials Logo

Pancreas Adenocarcinoma clinical trials

View clinical trials related to Pancreas Adenocarcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02707328 Terminated - Pancreatic Cancer Clinical Trials

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Start date: January 2015
Phase: Phase 1
Study type: Interventional

This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.

NCT ID: NCT01413087 Terminated - Clinical trials for Pancreas, Adenocarcinoma

Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

LAPC-BC-819
Start date: September 2011
Phase: Phase 2
Study type: Interventional

This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and intravenously administered gemcitabine. Intratumoral injections of BC-819 will be performed using endoscopic ultrasound (EUS). Primary Objective: To assess the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. Secondary Objectives: To compare the effects of intratumoral injection of BC-819 administered in combination with intravenous gemcitabine vs. intravenous gemcitabine alone on: Overall survival, Response rate, Resectability of the target tumor lesion, Quality of life, Safety, Serological Tumor Marker: CA 19-9, Duration of response, Failure-free survival